Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 13/20 | 0.50 |
| ▸ | NSD2 | O96028 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673210 | 0.89 | KDM4E (0.61) | KDM4EUSP2ALDH1A1ARNSD2 | |
| SCHEMBL6783952 | 0.89 | KDM4E (0.61) | KDM4EUSP2ALDH1A1ARNSD2 | |
| SCHEMBL12188729 | 0.84 | AR (0.55) | KDM4EUSP2ALDH1A1ARPGR | |
| SCHEMBL24838808 | 0.82 | KDM4E (0.44) | KDM4EALDH1A1ATM | |
| SCHEMBL2786569 | 0.82 | AR (0.58) | KDM4EUSP2ALDH1A1ARPGR | |
| SCHEMBL11857134 | 0.82 | AR (0.50) | KDM4EUSP2ALDH1A1ARPGR | |
| SCHEMBL25077588 | 0.82 | AR (0.50) | KDM4EUSP2ALDH1A1ARPGR | |
| SCHEMBL7669160 | 0.82 | AR (0.50) | KDM4EUSP2ALDH1A1ARPGR | |
| SCHEMBL2787679 | 0.82 | AR (0.50) | KDM4EUSP2ALDH1A1ARPGR | |
| SCHEMBL25735784 | 0.82 | AR (0.50) | KDM4EUSP2ALDH1A1ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| EP-3541375-B1 | FACTOR XIIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3541375-B1 | FACTOR XIIA INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-3773555-A1 | FACTOR XIIA INHIBITORS | University of Leeds (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-10875851-B2 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875851-B2 | Factor XIIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190352294-A1 | Factor XIIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190352294-A1 | Factor XIIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-11-21 | — | — | US | disclosed |
| WO-2019186164-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2019-10-03 | — | — | WO | disclosed |
| WO-2018093695-A1 | FACTOR XIIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2017024996-A1 | HYDROXY AMIDINE DERIVATIVE, PREPARATION METHOD AND USE IN MEDICINE THEREOF | 江苏恒瑞医药股份有限公司 | 2017-02-16 | — | — | WO | disclosed |
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| US-6900319-B2 | Thrombin inhibitors | ABBOTT GMBH & CO. KG (DE) | 2005-05-31 | — | — | US | disclosed |
| US-20020169318-A1 | Novel thrombin inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2002-11-14 | — | — | US | disclosed |
| US-6444817-B1 | ANTICOAGULANTS | ABBOTT LABORATORIES | 2002-09-03 | — | — | US | disclosed |
| US-6030972-A | 2- OR 5-AMINOMETHYL,2- OR 5-CYANOPYRIMIDINES AS INTERMEDIATES OF ANTICOAGULANTS IN EXTRACORPOREAL CIRCULATION (HEART-LUNG MACHINE, HEMODIALYSIS) | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| EP-0873356-A1 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-28 | — | — | EP | disclosed |
| WO-1996025426-A9 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | — | 1997-06-12 | — | — | WO | disclosed |
| WO-1996025426-A1 | NOVEL DIPEPTIDE AMIDINES AS THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | KDM4E 2571/4885USP2 4598/4885ALDH1A1 1197/4885 |
| US-10875851-B2 | Factor XIIa inhibitors | F11, F13B, SERPINC1 | KDM4E 1232/4885USP2 2934/4885ALDH1A1 1906/4885 |
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | F11, F13B, F12 | KDM4E 1509/4885USP2 3655/4885ALDH1A1 1427/4885 |
| US-20020169318-A1 | Novel thrombin inhibitors | TFPI, SERPINC1, F11 | KDM4E 4081/4885USP2 3179/4885ALDH1A1 925/4885 |
| US-20190352294-A1 | Factor XIIa Inhibitors | F11, F13B, SERPINC1 | KDM4E 1232/4885USP2 2934/4885ALDH1A1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.